Who / What
Plus Therapeutics, Inc. is a U.S. clinical-stage pharmaceutical company. It develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers.
Background & History
The company is headquartered in Houston, Texas. It has advanced its lead investigational candidate into clinical trials for several serious brain cancers.
Why Notable
The company is notable for its focus on developing targeted radiopharmaceuticals for difficult-to-treat brain and CNS cancers. Its lead candidate, REYOBIQ™, is a significant investigational therapy undergoing clinical evaluation for conditions like recurrent glioblastoma and leptomeningeal metastases.
In the News
The company remains relevant as REYOBIQ™ (rhenium Re-186 obisbemeda) continues its clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Its status as an investigational therapy keeps it active in the pharmaceutical development landscape.
